Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27001733 | 0.82 | ALDH1A1 (0.41) | ARPOLBMCHR1MAOB | |
| SCHEMBL1855982 | 0.82 | AR (0.49) | ARSLC6A4TRPV4 | |
| SCHEMBL411153 | 0.80 | AR (0.47) | ARSLC6A4TRPV4 | |
| SCHEMBL28057085 | 0.78 | AR (0.45) | ARSLC6A4TRPV4 | |
| SCHEMBL27001732 | 0.77 | ABCB1 (0.42) | ARPOLB | |
| SCHEMBL3288455 | 0.77 | AR (0.47) | ARSLC6A4 | |
| SCHEMBL7667004 | 0.77 | AR (0.47) | ARSLC6A4TRPV4 | |
| SCHEMBL22481567 | 0.77 | AR (0.47) | ARSLC6A4TRPV4 | |
| SCHEMBL3551458 | 0.77 | AR (0.47) | ARSLC6A4TRPV4 | |
| SCHEMBL14174964 | 0.77 | ACHE (0.48) | POLBPKMALOX15BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | TYR, ALK, TYRO3 | AR 1151/4885POLB 2292/4885PKM 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.